Suppr超能文献

病例报告:在具有有利免疫微环境的远处转移性淋巴结的胆囊癌患者中,在原发性肿瘤切除后联合免疫治疗实现持久完全缓解。

Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.

机构信息

Department of Organ Transplantation, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.

Department of Medicine, YuceBio Technology Co. Ltd., Shenzhen, China.

出版信息

Front Immunol. 2022 Feb 15;13:820566. doi: 10.3389/fimmu.2022.820566. eCollection 2022.

Abstract

BACKGROUND

Metastatic gallbladder carcinoma (GBC) is one of the most aggressive malignancies. As GBC is usually diagnosed with distant metastases, only a few patients can receive R0 resection and the relapse rate remains high. Programmed cell death protein 1 (PD-1) blockade therapy has provided encouraging long-term outcomes in a subset of patients in many cancers. However, the data on efficacy of PD-1 blockade in GBC are very limited.

CASE PRESENTATION

We herein reported a stage IVB GBC patient with localized primary tumor and distant lymph node metastasis. Except for the unresectable multiple metastatic nodes including distant nodes, a complete resection of primary tumor with partial segment 4B+5 was performed. Tumor tissues of primary tumor and one metastatic lymph node were collected to perform whole-exome sequencing, RNA-seq, and immunohistochemistry. Low TMB (5.38 muts/Mb), low MSI (<20%), and negative PD-L1 expression (TC0) were observed in the primary tumor. Likewise, low TMB (5.44 muts/Mb), low MSI (<20%), and low PD-L1 expression (TC2) presented in the metastatic lymph node. Besides, low genetic intratumor heterogeneity exhibited between the primary and metastatic tumors in this patient. In contrast to the primary tumor, higher-level CD8 T cell infiltration was revealed in the tumor microenvironment of the metastatic lymph node. Then, chemo-immunotherapy using S1 and anti-PD-1 antibody pembrolizumab was administrated as the first-line treatment for the residual metastatic nodes. Complete response was achieved after 7 courses and has lasted for 32 months up to present. Additionally, blood samples during treatment were further analyzed for immune repertoire sequencing, showing that several T cell receptor clones in metastatic lymph node were predominant in blood during the combined anti-PD-1 treatment.

CONCLUSIONS

Chemo-immunotherapy may provide a potential curative option for the lymph node metastases of gallbladder cancer. The low intratumor heterogeneity and high level of infiltrating CD8 T-cells in metastatic node might be indispensable to the durable complete response in this patient.

摘要

背景

转移性胆囊癌(GBC)是最具侵袭性的恶性肿瘤之一。由于 GBC 通常在远处转移时被诊断出来,只有少数患者能够接受 R0 切除,而且复发率仍然很高。程序性死亡蛋白 1(PD-1)阻断疗法在许多癌症的一部分患者中提供了令人鼓舞的长期结果。然而,关于 PD-1 阻断在 GBC 中的疗效数据非常有限。

病例介绍

我们在此报告了一名 IVB 期 GBC 患者,其局部原发肿瘤和远处淋巴结转移。除了无法切除的包括远处淋巴结在内的多个转移性淋巴结外,还对原发肿瘤进行了完全切除,部分切除了 4B+5 段。收集原发肿瘤和一个转移性淋巴结的肿瘤组织进行全外显子测序、RNA-seq 和免疫组化。在原发肿瘤中观察到低 TMB(5.38 muts/Mb)、低微卫星不稳定性(<20%)和 PD-L1 表达阴性(TC0)。同样,在转移性淋巴结中也观察到低 TMB(5.44 muts/Mb)、低微卫星不稳定性(<20%)和低 PD-L1 表达(TC2)。此外,与原发肿瘤相比,该患者的原发肿瘤和转移肿瘤之间的遗传肿瘤内异质性较低。与原发肿瘤相比,在转移性淋巴结的肿瘤微环境中发现了更高水平的 CD8 T 细胞浸润。然后,采用替吉奥联合抗 PD-1 抗体帕博利珠单抗作为一线治疗方案治疗残余转移性淋巴结。7 个疗程后达到完全缓解,截至目前已持续 32 个月。此外,在治疗期间进一步分析了血液样本的免疫受体测序,结果表明在联合抗 PD-1 治疗期间,转移性淋巴结中的几个 T 细胞受体克隆在血液中占优势。

结论

化疗免疫治疗可能为胆囊癌淋巴结转移提供一种潜在的治愈选择。转移淋巴结中低肿瘤内异质性和高水平浸润的 CD8 T 细胞可能是该患者持久完全缓解所必需的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/8887603/4955360bde20/fimmu-13-820566-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验